Impression receives research & development grant

|

Published 16-NOV-2017 13:06 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Impression Healthcare (ASX:IHL), an Australian ‘dental-impression’ company, has received $263,279 from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2017 financial year.

The funds will be deployed to further Impression’s direct business strategy of offering consumers a high-quality and more-affordable night guard for the treatment of bruxism (teeth grinding and clenching) without the need to be prescribed or fitted by a dentist.

Impression has developed several unique products for the DIY-dental market niche and intends to scale-up its activities over time via product development, wider distribution reach and higher unit sales.

The Knight Guard is an effective means of mitigating bruxism while The Sleep Guardian is a anti-snoring device. These products are attempting to satiate a significant and growing demand for affordable and customised dental devices, without high expenses or having to visit a dentist.

knightguard

Earlier this month, Impression sold its 1,000th unit of the Knight Guard.

Both the Sleep Guardian and the Knight Guard use an impression kit manufactured by qualified dental technicians at Impression’s laboratory in Victoria, Australia. All customers are able to access the full spectrum of functionality Impression has access to.

According to Impression, both the Knight Guard and Sleep Guardian are “relatively higher-value products that are markedly increasing revenue flow and reduce seasonality of sales”. November’s sales figures rising 83% month-to-date and 89% on a quarterly basis and Impression reports that there have been 7,593 unique visits to its website and 140,000 views of its product-specific Facebook page.

Despite the growth this remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.

Impression will utilise the funds raised from recent capital raisings to expand its digital marketing, print and TV advertising campaigns in order to educate customers about Impression’s products as well as to scale up its company operations.

Impression is also evaluating the possibility of working with complementary service providers (such as sleep therapists) as affiliates, who would be in a position to promote the Sleep Guardian/Knight Guard.

sleep guardian IHL

Impression could not provide further information regarding its intended affiliate programme but did confirm it “will update the market as and when any formal arrangements may be executed.”

Impression’s current CEO Matt Weston said, “New product offerings recently introduced are helping sales momentum and we continue to evaluate initiatives in the pipeline that will increase brand value and increase sales across our suite of products.”

“Early sales of the Sleep Guardian have been procured on minimal marketing spend to date and we look forward to increasing sales of the Sleep Guardian with a co-ordinated marketing campaign to commence in early 2018.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X